Conference Reports for NATAP

Back

57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) October 27-31, 2006 Boston, MA     In Vitro Synergistic Antiviral Activity of ITMN-191, an Orally Active Inhibitor of the Hepatitis C Virus (HCV) NS3/4A Protease, in Combination with PEG-Interferon Alfa-2a - (11/14/06)   Development of HCC in Patients who Achieve SVR to IFN-Based Therapies is Associated with Cirrhosis and Prior HBV Exposure - (11/14/06)   CPG10101 HCV Toll-Receptor 9 Antagonist Phase II Study results - (11/10/06)   New HBV Drug PMEO-DAPym Active In Vitro Against Drug Resistant Mutants of HBV - (11/10/06)   In Vitro Resistance Studies of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-dependent RNA Polymerase - (11/08/06)   No Novel Adefovir Mutations - (11/08/06)   Pegasys/RBV Prophylaxisly Administered After Liver Transplant - (11/08/06)   RBV Exposure During weeks 1-12 of Treatment Improves SVR Rate in Canadian Pegasys EAP - (11/08/06)   Early predictors of anemia in patients with HCV genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin 1000-1200 mg/day - (11/08/06)   PegIntron/RBV Effective for >65 Year Olds - (11/08/06)   New Therapy Significantly Increases Platelet Count - (11/08/06)   Eltrombopag, an Oral Platelet Growth Factor, Facilitates Initiation of Interferon Therapy in Subjects with HCV Associated Thrombocytopenia - (11/08/06)   Merck HCV Polymerase Inhibitor - (11/08/06)   In Vitro Resistance Studies of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-dependent RNA Polymerase - (11/08/06)   Pegasys + Adefovir Reduces HBsAg in HDV-Coinfected - (11/07/06)   Pegasys+Lamivudine for HBeAg-negative, 2 Year Follow-up - (11/07/06)   Pegasys 270 ug/wk+RBV 1200/1600mg in Difficult To Treat Patients - (11/07/06)   Pegasys Every 5 Days in PegIntron Nonresponders - (11/07/06)   Hispanic Responses to PegIntron/RBV in WIN-R Study - (11/07/06)   LATINO Pegasys Study: early responses - (11/07/06)   Anti-HBV Activity of In Vitro Combinations of Tenofovir with Nucleoside Analogs - (11/06/06)   In Vitro Susceptibility of HBV Polymerase Encoding Mutations Acquired During Adefovir Dipivoxil Therapy to Other Anti-HBV Agents - (11/06/06)   Adefovir 3 & 5 Years Followup HBeAg+: safety & efficacy - (11/06/06)   16 vs 24 weeks Pegasys/RBV for Genotype 2 HCV; Taiwan Study: Week 4 Response & Ribavirin Level/Dose Predicts SVR - (11/06/06)   <400,000 is New HCV RNA Cutoff In genotype 1 with Pegasys/RBV - (11/06/06)   72 Weeks Pegasys/RBV in Genotype 1 Improves SVR Rate For Patients With Early Viral Response (2 log reduction at wk 12) But HCV RNA >50 IU/mL - (11/06/06)   72 Weeks Peg/RBV for 'Slow-Responders' Improves SVR Rate - (11/06/06)   400,000 IU/ml was the best cut-off level between Low VL and High VL - (11/06/06)   The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naive HIV/HCV co-infected subjects - (11/03/06)   Entecavir vs Adefovir in HBeAg+ Naives 24 Weeks EARLY Study - (11/03/06)   Ribavirin Dose/Levels Predicts Outcome in Pegasys/RBV ACCELERATE Study Comparing 16 vs 24 Weeks Therapy - (11/03/06)   Week 4 Response Predicts SVR in Pegasys/RBV 16 Week Therapy Study in Genotypes 2/3 - (11/03/06)   Weight-Based Ribavirin Improves SVR Rate for Patients >125 kg (275 lbs) - (11/02/06)   Infergen (Consensus Interferon) Phase III DIRECT Study End of Treatment Results - (11/02/06)   Current status of Subjects Receiving Pegays and Ribavirin Follow-On Therapy After 28 Days Treatment with the Hepatitis C Protease Inhibitor Telaprevir (VX-950), Pegasys & RBV - (11/02/06)   Win-R Study: Ribavirin Weight-Base Dosing in High Weight Patients; Treatment Responses to PegIntron/RBV for Elderly Patients and by Patient Ethnicity - (11/02/06)   Entecavir Resistance 3-Year Update at AASLD - (11/02/06)   Entecavir 3-Year Resistance Update - (11/02/06)   Entecavir 3-Year Efficacy/Safety Update in HBeAg+ Naives - (11/02/06)   Entecavir 3-Year Update on Efficacy & Safety - (11/02/06)   Two-Year Results from the GLOBE Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine - (11/01/06)   VX-950 HCV Protease Inhibitor Resistance Profile: combination therapy suppresses drug resistance - (11/01/06)   New Drug Lowers AST/ALT Levels in Chronic HCV - (11/01/06)   Albuferon Phase 2 Study Results Reported in Posters at AASLD - (11/01/06)   Albuferon Quality-Of-Life Reported - (11/01/06)   Roche HCV Polymerase Inhibitor Shows Potency: 4 log viral load reduction - (10/31/06)   Valopicitabine (NM283) plus Peg-Interferon in Treatment-Naive Hepatitis C Patients with HCV Genotype-1 Infection: HCV RNA Clearance During 24 Weeks of Treatment - (10/31/06)   SELECTION AND CHARACTERIZATION OF HEPATITIS C VIRUS REPLICONS RESISTANT TO A POTENT POLYMERASE INHIBITOR A-837093 - (10/30/06)   In vitro antiviral effects of combinations of Abbott HCV polymerase inhibitors with IFN or NS3/4A protease inhibitors - (10/30/06)   The Antiviral Efficacy of an HCV Polymerase inhibitor in the Chimpanzee Model: Genotypic and Phenotypic Analysis - (10/30/06)   Coffee Appears to Reduce Risk of Fibrosis in HCV+ - (10/30/06)   Daily Cannabis Use by HCV+ Increased Odds of Moderate to Severe Fibrosis by 7- Fold - (10/30/06)   Higher Fixed Dosing with PEGASYS in Difficult-to-Treat Patients - (10/30/06)   Early Week 4 Response Predicts SVR in Genotype 1 - (10/30/06)   Roche's Oral Polymerase Inhibitor R1626 Shows Strong Antiviral Activity in Chronic Hepatitis C Patients - (10/30/06)   Update on NM283, HCV Polymerase Inhibitor, at New 200 mg Dose - (10/30/06)   New Data for Investigational Hepatitis C Drug Telaprevir (VX-950) to be Presented at AASLD Meeting - (10/30/06)   Valeant Pharmaceuticals Previews 24-Week Results of Direct Trial for Infergen (Consensus Interferon) - (10/30/06)